Dana-Farber's Toni Choueiri, MD, provides insight on KEYNOTE-564 trial in kidney cancer highlighted at ESMO 2021.
I'm Tony sherry from the Dana Farber Cancer Institute And during the 2021 virtual ehsmoh meeting, we had the chance to present a follow up study from keynote 56 14 0564 is a phase three trial of patriotism and versus placebo in the advent therapy for patients with renal cell carcinoma. This study already just published showing 32% decrease in the risk of recurrence or death with embolism over placebo. So what we presented that asthma 2021 was the patient reported outcome and quality of life. Since we collected that on study, we focus our instrument on to patient reported outcome P. R. O. Instrument fKS I. DRS which associates symptoms with kidney cancer here with higher score representing better symptoms status and the RtC. That's the second instrument, the RtC. Q L Q C 30 C 30 which is multiple, nine items scales, some functional some symptoms scale and one quality of life scale. And we found what we found consistently Is that there was no clinically meaningful differences and health-related quality of life or symptoms. Scores with either pay embolism or placebo and the scores in both treatment group remained actually stable over the reported study period. And when you look at the data and more detail than 95% confidence interval really overlap at all times The disease-related symptoms were rarely severe at this disease stage. So these patient reported outcome results from Keen on 564 are very important why because they support the reported efficacy and the safety findings of the first analysis of Keynote 564 that we presented at the 2021 AsCO in june and published in the New England Journal of Medicine. It all converged into the fact that pembroke role is a mob is a potential new standard of care for patients with renal cell cancer in the agreement setting.